Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 3,800 shares of the business's stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $4.04, for a total transaction of $15,352.00. Following the completion of the sale, the insider owned 555,559 shares in the company, valued at $2,244,458.36. This represents a 0.68% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Chidozie Ugwumba also recently made the following trade(s):
- On Friday, January 30th, Chidozie Ugwumba sold 5,686 shares of Clene stock. The stock was sold at an average price of $4.13, for a total transaction of $23,483.18.
- On Thursday, January 29th, Chidozie Ugwumba sold 15,284 shares of Clene stock. The shares were sold at an average price of $4.32, for a total transaction of $66,026.88.
- On Wednesday, January 28th, Chidozie Ugwumba sold 8,717 shares of Clene stock. The stock was sold at an average price of $4.91, for a total transaction of $42,800.47.
- On Tuesday, January 27th, Chidozie Ugwumba sold 4,139 shares of Clene stock. The stock was sold at an average price of $5.08, for a total transaction of $21,026.12.
- On Monday, January 26th, Chidozie Ugwumba sold 6,418 shares of Clene stock. The shares were sold at an average price of $5.02, for a total transaction of $32,218.36.
- On Friday, January 23rd, Chidozie Ugwumba sold 5,556 shares of Clene stock. The stock was sold at an average price of $5.27, for a total value of $29,280.12.
- On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The shares were sold at an average price of $5.32, for a total value of $67,377.80.
- On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The shares were sold at an average price of $5.05, for a total value of $61,200.95.
- On Tuesday, January 20th, Chidozie Ugwumba sold 12,432 shares of Clene stock. The stock was sold at an average price of $4.80, for a total value of $59,673.60.
- On Friday, January 16th, Chidozie Ugwumba sold 7,923 shares of Clene stock. The shares were sold at an average price of $5.13, for a total value of $40,644.99.
Clene Stock Down 1.2%
Shares of NASDAQ CLNN opened at $4.04 on Tuesday. The firm's 50-day simple moving average is $6.24 and its 200 day simple moving average is $6.56. The company has a market cap of $43.83 million, a price-to-earnings ratio of -1.19 and a beta of 0.87. Clene Inc. has a 12-month low of $2.28 and a 12-month high of $13.50.
Clene (NASDAQ:CLNN - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.06 million. On average, equities analysts expect that Clene Inc. will post -5.19 earnings per share for the current year.
Analyst Ratings Changes
Several research firms have recently commented on CLNN. Benchmark reissued a "buy" rating on shares of Clene in a research note on Thursday, December 4th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Clene in a research report on Friday, January 9th. D. Boral Capital restated a "buy" rating and set a $23.00 target price on shares of Clene in a research report on Friday, January 9th. Finally, UBS Group reaffirmed a "buy" rating on shares of Clene in a research note on Wednesday, December 3rd. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $32.60.
Check Out Our Latest Stock Analysis on Clene
Hedge Funds Weigh In On Clene
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLNN. Scoggin Management LP grew its position in shares of Clene by 75.1% during the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company's stock worth $1,506,000 after buying an additional 107,250 shares during the period. Lunt Capital Management Inc. boosted its stake in Clene by 2.5% during the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company's stock worth $315,000 after acquiring an additional 1,250 shares during the last quarter. Jane Street Group LLC acquired a new position in Clene during the second quarter valued at approximately $47,000. Finally, Jones Financial Companies Lllp bought a new stake in Clene in the third quarter valued at approximately $29,000. Institutional investors own 23.28% of the company's stock.
About Clene
(
Get Free Report)
Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.
Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
